Kyntra BioLTS:0IL8 52 EBITDA Margin % is -339.70% as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 52/100 and a GF Value™ of $5.68 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 945 Biotechnology companies, Kyntra Bio ranks worse than 74.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kyntra Bio's EBITDA for the
three
months ended in Mar. 2026 was $-12.70 Mil. Kyntra Bio's Revenue for the
three
months ended in Mar. 2026 was $3.74 Mil. Therefore, Kyntra Bio's EBITDA margin for the quarter that ended in Mar. 2026 was -339.70%.
Kyntra Bio (LTS:0IL8) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kyntra Bio EBITDA Margin % Related Terms
Kyntra Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs SER, SNSE, PVCT: EBITDA Margin % Comparison
For the Biotechnology subindustry, Kyntra Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a EBITDA Margin % of -339.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #703 out of 945 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Kyntra Bio's EBITDA Margin % too high?
Kyntra Bio's current EBITDA Margin % is -339.70%. Based on the distribution chart, Kyntra Bio ranks #703 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's EBITDA Margin % compare to SER and SNSE?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #703 out of 945 companies for EBITDA Margin %. This places Kyntra Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current EBITDA Margin % is -339.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $6.86 — trading 20.7% above its estimated fair value. The current EBITDA Margin % is -339.70%. Kyntra Bio's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current EBITDA Margin % is -339.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $6.86 is trading 20.7% above its estimated GF Value™ of $5.68.
GuruFocus considers Kyntra Bio to be Modestly Overvalued.
Key valuation signals for LTS:0IL8:
EBITDA Margin %: -339.70%
GF Value™: $5.68 vs. price of $6.86 (20.7% above fair value)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
52GF Score
Get the complete analysis for LTS:0IL8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
